We tracked 27 orthopedic funding announcements worth over $830 million in the 12-month period between October 2022 and September 2023. Investors focused heavily on enabling technology during that period, which accounted for a third of all funding announcements and totaled more than $342 million.
For context, enabling technology presented 16% of orthopedic funding announcements from 2016 to 2022. The increased focus on technology came mostly at the expense of spine and trauma as they slowed against their historical volume averages.
It is a good time to be a start-up in the commercialization stage, according to Gary Stevenson, Co-Founder and Managing Partner of MB Venture Partners. “It is the best of times for startups in the commercialization stage because raising growth capital has been robust in 2023,” he said. “Capital raises to fund new product development or PMA studies are much harder to close. Investors are reluctant to take the clinical, regulatory or reimbursement risk often associated with early-stage startups.”
Many of the enabling technology companies that presented at last year’s Musculoskeletal New Ventures Conference (MNVC) focused on improving the economic value proposition, particularly in spine surgery. We expect that trend to continue this year as well.
We tracked 27 orthopedic funding announcements worth over $830 million in the 12-month period between October 2022 and September 2023. Investors focused heavily on enabling technology during that period, which accounted for a third of all funding announcements and totaled more than $342 million.
For context, enabling technology presented 16%...
We tracked 27 orthopedic funding announcements worth over $830 million in the 12-month period between October 2022 and September 2023. Investors focused heavily on enabling technology during that period, which accounted for a third of all funding announcements and totaled more than $342 million.
For context, enabling technology presented 16% of orthopedic funding announcements from 2016 to 2022. The increased focus on technology came mostly at the expense of spine and trauma as they slowed against their historical volume averages.
It is a good time to be a start-up in the commercialization stage, according to Gary Stevenson, Co-Founder and Managing Partner of MB Venture Partners. “It is the best of times for startups in the commercialization stage because raising growth capital has been robust in 2023,” he said. “Capital raises to fund new product development or PMA studies are much harder to close. Investors are reluctant to take the clinical, regulatory or reimbursement risk often associated with early-stage startups.”
Many of the enabling technology companies that presented at last year’s Musculoskeletal New Ventures Conference (MNVC) focused on improving the economic value proposition, particularly in spine surgery. We expect that trend to continue this year as well.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
